|Day Low/High||120.99 / 125.70|
|52 Wk Low/High||121.83 / 199.00|
In plain speak, they ran for the exits on Wednesday, This week has been a period of intense institutional distribution.
BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.
The charts and indicators of SGEN are looking healthy.
The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
Stocks are reasonable. Or even cheap. There will be more sell-offs ahead but remember this day and do not get too negative.
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
We've become accustomed lately to gap-up opens on Mondays, but some fresh acquisition agreements are helping drive this Monday's action.
The firm is obviously fast becoming a real player in creating treatment for certain cancers. The firm still loses money.
This biotech is on the front lines of oncology treatments.
Time to check the charts and indicators.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Good morning folks! As Doug heads off on vacation (something I'll be doing on Saturday myself), I'm sitting in today for him, and I'll be doing so again right before his return. We're in the second real week of the June-quarter earnings season, and ...
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
The Menlo Park, Calif.-based firm on Thursday reported third-quarter results and said it has hired Cowen to help with evaluating potential transactions.
The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.
Stocks were up midday Tuesday as the Dow moves toward the 20,000 milestone and consumer confidence increases.
Selling in SGEN has created a huge upside vacuum; take advantage with this vertical call spread strategy.
The trade is once again the out-of-the-money, bullishly biased vertical call spread.
Shares of Grand Canyon Education (LOPE) have fallen over 18% so far in 2015, but they have still outperformed the rest of the beleaguered for-profit education sector.